Fezagepras sodium - 10mM in DMSO , CAS No.1254472-97-3

CAS: 1254472-97-3 Cat. No.: F656175 Molecular Weight: 228.26 EC Number: 879-954-2 PubChem CID: 46944243
AVAILABLE TO ORDER
GRADE & PURITY 10mM in DMSO
Storage
Desiccated,Store at -80°C
Shipped In
Dry ice packs + Cold packs
 ·  off list, applied to all prices below.
Size
Status
Price
Qty
1ml
F656175-1ml
8-12 wks(?) Production requires sourcing of materials. We appreciate your patience and understanding.
$396.90
Enter a quantity for the sizes you want to add.
🧪

Why this grade

10mM in DMSO for sensitive chromatographic and analytical workflows requiring minimal baseline interference.

🌡

Storage & shipping

Desiccated,Store at -80°C Ships Dry ice packs + Cold packs Check lot-specific COA for exact specifications.

📋

Quality documents

SDS, COA, datasheet, and spec sheet available for download. Lot-specific COA accessible via lot number lookup.

📚

Literature proof

Cited in 0 peer-reviewed publications across chromatography, organic synthesis, and cross-coupling reactions.

Overview

Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84 Fezagepras sodium decreases renal, liver and pancreatic fibrosis Fezagepras sodium exerts anti-fibrotic, anti-inflammatory and anti-proliferative actions .

In Vitro

Fezagepras sodium (500 μM; 24 hours) inhibits TGF-β (10 ng/mL)-activated human hepatic stellate cells (HSCs) proliferation. ?\nFezagepras sodium (250 or 500 μM; 24 hours) dose-dependently arrests HSCs at the G0/G1 phase without inducing apoptosis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: HSCs Concentration: 250 or 500 µM Incubation Time: 24 hours Result: Inhibited TGF-β-activated HSC proliferation. TGF-β (10 ng/mL) increased HSC proliferation by 10%. Cell Cycle AnalysisCell Line: HSCs Concentration: 250 µM, 500 µM Incubation Time: 24 hours Result: Inhibited cell cycle progression.

In Vivo

Fezagepras sodium (100 mg/kg/day; gavage from 8-20 weeks of age) markedly decreases hyperglycemia and markedly improvea glucose tolerance in type 2 diabetes eNOS -/- db/db mice .· MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Type 2 diabetes eNOS -/- db/db mice Dosage: 100 mg/kg/day Administration: Given via daily gavage from 8-20 weeks Result: Compared with vehicle-treated mice, hyperglycemia was markedly decreased, and glucose tolerance was markedly improved.

IC50& Target:GPR40, GPR84

Specifications

Specifications & Purity
10mM in DMSO
Biochemical and Physiological Mechanisms
Fezagepras (Setogepram) sodium acts as an orally active agonist for GPR40 and as an antagonist or inverse agonist for GPR84. Fezagepras sodium decreases renal, liver and pancreatic fibrosis. Fezagepras sodium exerts anti-fibrotic, anti-infla
Storage
Desiccated, Store at -80°C
Shipped In
Dry ice packs + Cold packs
This product requires cold chain shipping. Ground and other economy services are not available.
Action Type
AGONIST
Names and Identifiers
Isomeric SMILES CCCCCC1=CC(=CC=C1)CC(=O)[O-].[Na+]
Alternate CAS 1254472-97-3
PubChem CID 46944243
Molecular Weight 228.26

Documentation

📋 Safety Data Sheet (SDS)

Comprehensive hazard, handling, storage, and regulatory compliance document.

Download SDS →

✅ Certificate of Analysis (COA)

Lot-specific quality data. Enter your lot number to retrieve the exact COA.

Look up COA →

📊 Datasheet

Quick-reference summary of product specifications and applications.

View datasheet →

🔬 Specification Sheet

Full quality attributes and acceptance criteria for this grade.

View spec sheet →

Advanced Data

Certificates(CoA,COO,BSE/TSE and Analysis Chart)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Solution Calculators
Reviews

Customer Reviews

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.